ES2326337T3 - Nuevas pirrolodihidroisoquinolinas como inhibidores de pde10. - Google Patents

Nuevas pirrolodihidroisoquinolinas como inhibidores de pde10. Download PDF

Info

Publication number
ES2326337T3
ES2326337T3 ES06701124T ES06701124T ES2326337T3 ES 2326337 T3 ES2326337 T3 ES 2326337T3 ES 06701124 T ES06701124 T ES 06701124T ES 06701124 T ES06701124 T ES 06701124T ES 2326337 T3 ES2326337 T3 ES 2326337T3
Authority
ES
Spain
Prior art keywords
quad
alkyl
alkoxy
hydrogen
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06701124T
Other languages
English (en)
Spanish (es)
Inventor
Jean-Marie Contreras
Paola Ciapetti
Camille Georges Wermuth
Jurgen Braunger
Thomas Bar
Matthias Vennemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Application granted granted Critical
Publication of ES2326337T3 publication Critical patent/ES2326337T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES06701124T 2005-01-12 2006-01-11 Nuevas pirrolodihidroisoquinolinas como inhibidores de pde10. Active ES2326337T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05100154 2005-01-12
EP05100154 2005-01-12

Publications (1)

Publication Number Publication Date
ES2326337T3 true ES2326337T3 (es) 2009-10-07

Family

ID=36097003

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06701124T Active ES2326337T3 (es) 2005-01-12 2006-01-11 Nuevas pirrolodihidroisoquinolinas como inhibidores de pde10.

Country Status (9)

Country Link
US (1) US20080161338A1 (enExample)
EP (1) EP1838707B1 (enExample)
JP (1) JP2008526818A (enExample)
AT (1) ATE430148T1 (enExample)
AU (1) AU2006218054A1 (enExample)
CA (1) CA2593750A1 (enExample)
DE (1) DE602006006544D1 (enExample)
ES (1) ES2326337T3 (enExample)
WO (1) WO2006089815A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200510407A (en) * 2003-06-30 2005-03-16 Altana Pharma Ag Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
EP1838708A2 (en) * 2005-01-12 2007-10-03 Nycomed GmbH Pyrrolodihydroisoquinolines as antiproliferative agents
US7875618B2 (en) * 2007-11-30 2011-01-25 Wyeth Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders
WO2009070583A1 (en) * 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
TW200944523A (en) 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
SG192839A1 (en) 2011-02-18 2013-09-30 Allergan Inc Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
GB201117453D0 (en) * 2011-10-10 2011-11-23 Univ Dundee Improved sperm function/activity
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CN119367368B (zh) * 2024-11-28 2025-12-05 中山大学 氮杂四元环连接的吡唑并吡啶类化合物在制备治疗肺动脉高压的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6930114B2 (en) * 2000-12-13 2005-08-16 Bayer Pharmaceuticals Corporation Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) * 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
US20030018047A1 (en) * 2001-04-20 2003-01-23 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
WO2003014115A1 (en) * 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
AU2002366362A1 (en) * 2001-12-18 2003-06-30 Bayer Aktiengesellschaft 2-substituted pyrrolo(2.1-a)isoquinolines against cancer
TW200510407A (en) * 2003-06-30 2005-03-16 Altana Pharma Ag Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors

Also Published As

Publication number Publication date
AU2006218054A1 (en) 2006-08-31
ATE430148T1 (de) 2009-05-15
EP1838707B1 (en) 2009-04-29
JP2008526818A (ja) 2008-07-24
US20080161338A1 (en) 2008-07-03
EP1838707A1 (en) 2007-10-03
CA2593750A1 (en) 2006-08-31
DE602006006544D1 (de) 2009-06-10
WO2006089815A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
ES2331519T3 (es) Derivados de pirrolo-dihidroisoquinolina como inhibidores de pde10.
EP1641792B1 (en) Pyrrolodihydroisoquinolines as pde10 inhibitors
JP4523281B2 (ja) Ｈｉｖインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類
ES2286491T3 (es) Piperidina-ftalazonas sustituidas con pirrolidinadiona, como agentes inhibidores de la pde4.
KR102084109B1 (ko) 캡 의존적 엔도뉴클레아제 저해제 및 항인플루엔자 약을 조합하는 것을 특징으로 하는 인플루엔자 치료용 의약
ES2320487T3 (es) Pirrolopirimidinas utiles como inhibidores de proteina quinasas.
ES2380395T3 (es) Triazolopiridinas como inhibidores de fosfodiesterasa para el tratamiento de enfermedades dérmicas
PT1706403E (pt) Compostos de imidazo[4,5-c]piridina e métodos de tratamento antiviral
CA2989722C (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
CZ304344B6 (cs) Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
JP2015178457A (ja) ピラゾロピリジン誘導体、またはその薬理学的に許容される塩
MX2011009314A (es) Compuesto de quinoxalina.
JP6130828B2 (ja) キナゾリンジオン誘導体
JP2012522759A (ja) イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体
ES2326337T3 (es) Nuevas pirrolodihidroisoquinolinas como inhibidores de pde10.
AU2016258188B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EA016300B1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
BRPI0709595A2 (pt) inibidores de nf-kapab heterocìclicos
ES2286494T3 (es) Nuevas benzonaftiridinas.
TW202530189A (zh) ３－苯基丙基胺衍生物